company background image
2126 logo

JW (Cayman) Therapeutics SEHK:2126 Stock Report

Last Price

HK$2.15

Market Cap

HK$864.0m

7D

8.6%

1Y

-51.2%

Updated

29 Feb, 2024

Data

Company Financials +

JW (Cayman) Therapeutics Co. Ltd

SEHK:2126 Stock Report

Market Cap: HK$864.0m

2126 Stock Overview

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China.

2126 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

JW (Cayman) Therapeutics Co. Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for JW (Cayman) Therapeutics
Historical stock prices
Current Share PriceHK$2.15
52 Week HighHK$4.52
52 Week LowHK$1.58
Beta2.08
1 Month Change19.44%
3 Month Change-32.18%
1 Year Change-51.25%
3 Year Change-93.87%
5 Year Changen/a
Change since IPO-90.23%

Recent News & Updates

Recent updates

JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

Feb 03
JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?

Shareholder Returns

2126HK BiotechsHK Market
7D8.6%3.8%-1.8%
1Y-51.2%-42.5%-15.2%

Return vs Industry: 2126 underperformed the Hong Kong Biotechs industry which returned -42.7% over the past year.

Return vs Market: 2126 underperformed the Hong Kong Market which returned -15.1% over the past year.

Price Volatility

Is 2126's price volatile compared to industry and market?
2126 volatility
2126 Average Weekly Movement8.6%
Biotechs Industry Average Movement9.7%
Market Average Movement7.1%
10% most volatile stocks in HK Market14.4%
10% least volatile stocks in HK Market3.5%

Stable Share Price: 2126's share price has been volatile over the past 3 months.

Volatility Over Time: 2126's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016490James Lihttps://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People’s Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co. Ltd Fundamentals Summary

How do JW (Cayman) Therapeutics's earnings and revenue compare to its market cap?
2126 fundamental statistics
Market capHK$863.99m
Earnings (TTM)-HK$867.31m
Revenue (TTM)HK$182.14m

4.7x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2126 income statement (TTM)
RevenueCN¥167.44m
Cost of RevenueCN¥87.00m
Gross ProfitCN¥80.44m
Other ExpensesCN¥877.73m
Earnings-CN¥797.30m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.98
Gross Margin48.04%
Net Profit Margin-476.18%
Debt/Equity Ratio15.8%

How did 2126 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.